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Introduction 
Primary intraocular lymphoma (PIOL) is 
a subset of primary central nervous system 
lymphoma (PCNSL).  PCNSL is usually a 
diffuse large B-cell non-Hodgkin’s 
lymphoma in which malignant lymphoid 
cells involve the retina, vitreous, or optic 
nerve, with or without concomitant CNS 
involvement.1,2  Because PIOL remains 
confined to neural structures, it is 
distinguished from primary orbital 
lymphoma and systemic non-Hodgkin’s 
lymphomas that either involve or 
metastasize via the circulation to the uvea 
and ocular adnexa of the orbit, lacrimal 
gland, and conjunctiva.3   
The incidence of PCNSL has increased 
in both immunocompetent and immuno-
compromised people from 0.027/100,000 in 
1973 to 1/100,000 in the early 1990s.4  The 
cause for the increased incidence in 
immunocompetent patients is unknown.5  
Ocular disease is bilateral in 80% of cases.6 
Previous reports suggested that 
approximately 80% of patients with PIOL 
subsequently will develop brain 
lymphoma.7-9 
This report highlights the need for 
collaboration to improve our understanding 
and management of rare malignancies such 
as PIOL. 
 
Case Report 
A 50-year-old male, initially presented 
for blurred vision, more pronounced on the 
left, of three weeks duration. Ophthalmo-
logic   exam    confirmed   the   presence   of  
 
scattered vitreous cells.  The eye angiogram 
was within normal limits and no findings 
were suggestive of papillitis. 
A workup, including complete blood 
count (CBC), angiotensin-converting 
enzyme level, Human Leukocyte Antigen-B 
27 and 51, antinuclear antibody test, and 
Rapid Plasma Reagin, was within normal 
limits except for a mild lymphocytosis. A 
hematology consult was requested.  
The workup for lymphoproliferative 
disorders included an erythrocyte sedi-
mentation rate (ESR), a positron emission 
tomography (PET) scan, a magnetic 
resonance imaging (MRI) of the brain, a 
bone marrow biopsy, blood flow cytometry, 
a lumbar puncture with flow cytometry and 
cytology, and a computed tomography (CT) 
scan of the chest, abdomen, and pelvis.  All 
exams were within normal limits.  
Over the next few months, the patient 
was treated with different modalities for 
vitreitis, including methotrexate, without 
improvement. Left vitrectomy was done 14 
months after initial presentation. The flow 
cytometry on the vitreous fluid showed 11% 
monoclonal type B lymphocytes with 
lambda light chain restriction. Another 
workup, including ESR, PET scan, MRI of 
the brain, bone marrow biopsy, blood flow 
cytometry, lumbar puncture with flow 
cytometry and cytology, CT scan of the 
chest, abdomen, and pelvis, was within 
normal limits.  The radiation oncologist was 
reluctant to consider this case as a primary 
intraocular lymphoma and to treat it as such.  
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The patient’s vision improved after 
vitrectomy.  However,   he   had   right-sided 
blurriness.  Right vitrectomy was done five 
months later.  Cytology and flow cytometry 
on the vitreous fluid confirmed the presence 
of a large B cell lymphoma with lambda 
light chain restriction. The workup for 
systemic involvement was again negative.  
The patient was treated with bilateral 
ocular radiation (6MV photons, 5 by 5.5 cm, 
to a dose of 3000 cGy in 200 cGy per 
fraction for 15 fractions). He was followed 
every six months with brain MRI, CBC, and 
a lumbar puncture with fluid cytology and 
cytometry without evidence of recurrence.  
The patient reported headaches two 
years later (almost four years from the initial 
presentation).  An MRI of the brain showed 
a large left frontal lobe tumor.  He was 
treated with two cycles of CHOP-R for a 
presumed large B cell lymphoma relapse.  
CHOP-R is named after the chemotherapy 
drugs used in the treatment.  It involves the 
monoclonal antibody rituximab, and the 
drugs: cyclophosphamide, doxorubicin 
(chemical name hydroxydaunorubicin), 
vincristine (originally known as Oncovin®) 
and prednisone. 
The repeat MRI after the two CHOP-R 
cycles showed regression of the lesion. The 
patient completed a total of four cycles of 
CHOP-R, then underwent debulking surgery 
followed by whole brain radiation therapy. 
The pathology confirmed the diagnosis of 
diffuse large B cell lymphoma. The patient 
underwent autologous stem cell 
transplantation eight months after beginning 
CHOP-R therapy, followed by five courses 
of intrathecal cytarabine. The patient 
remained disease free four years later.     
 
Discussion 
At presentation, PIOL often is 
misdiagnosed as uveitis and may respond 
initially to corticosteroids, resulting in a 
delay of definitive diagnosis.10  Patients may 
complain of blurred vision and floaters.  
Visual acuity often is better than would be 
expected based on the clinical 
examination.10-13 
Given the nonspecific nature of eye 
findings in PIOL, patients being considered 
for this diagnosis should be examined for 
other causes of uveitis, including 
sarcoidosis, intermediate uveitis, multifocal 
choroiditis, acute posterior multifocal 
placoid pigment epitheliopathy, birdshot 
chorioretinopathy, toxoplasmosis, ocular 
tuberculosis, and acute retinal necrosis.3 A 
diagnosis often is not made until there is 
brain progression at which time the 
prognosis is poor.14  The most common 
finding on ocular examination is vitreitis. 
The posterior segment examination usually 
reveals vitreous cells, which may form 
clumps or sheets.12,13 
PIOL is closely related to PCNSL.  It 
seldom involves other organs, therefore, 
neuroimaging of the brain, orbits, and a 
lumbar puncture are required.15,16 For 
patients with no evidence of disease by 
neuroimaging or cerebrospinal fluid (CSF), 
a diagnostic vitrectomy should be performed 
on the eye with the most severe vitreitis or 
poorest visual acuity.17   
It is difficult to arrive at a pathologic 
diagnosis of PIOL.7,18  Thus, research has 
focused on developing other methods to 
assist in the diagnosis of PIOL. These 
methods include immunohistochemistry, 
flow cytometry, molecular analysis, and 
cytokine evaluation.   
Immunohistochemistry and flow cyto-
metry rely on the finding that most PIOLs 
are monoclonal populations of B lympho-
cytes that stain for B-cell markers (CD19, 
CD20, CD22) and have restricted expression 
of kappa or lambda chains.13,19,20  Immuno-
histochemistry also has been used to demon-
strate expression of B-cell lymphoma-6 
(BCL-6) and multiple myeloma oncogene 1 
(MUM1) in PIOL cells.  
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BCL-6 is a B-cell marker that is 
normally turned off as B cells move from 
the germinal center into the marginal zone 
during B-cell differentiation.21  MUM1 is a 
protein involved in the control of plasma 
cell differentiation. While B cells usually 
express one of these proteins at a time, 
concomitant expression has been shown in 
systemic diffuse large B-cell lymphoma.22 
Similar patterns of expression also have 
been demonstrated in five patients with 
PIOL.23  Many still believe that a pathologic 
diagnosis is required to confirm the presence 
of PIOL and immunophenotyping plays a 
supportive role in diagnosis.3 
Ocular specimens from patients with 
PIOL revealed immunoglobulin heavy (IgH) 
rearrangements in the third comple-
mentarity-determining region (CDR3) of the 
IgH variable region that can serve as a 
molecular marker of clonal expansion of 
lymphocytes.24  Cytokines may play a role 
in distinguishing PIOL from uveitis. While 
interleukin 6 (IL-6) is produced in high 
levels by inflammatory cells in uveitis, IL-
10 is produced by malignant B lymphocytes 
in intraocular and CNS lymphoma.  PIOL is 
associated with an increased IL-10 to IL-6 
ratio (greater than 1.0).25  
These patients should undergo 
neuroradiologic imaging and CSF 
examination. No further ocular diagnostic 
tests are required in patients with positive 
CSF. In patients with negative CSF, a 
vitrectomy or vitreous tap should be 
performed in the eye with more severe 
vitreitis or worse visual acuity.  This sample 
should be sent for cytology, cytokine 
analysis, IgH rearrangements, Bcl-2/IgH 
translocations, and immunohistochemistry/ 
flow cytometry.  
Chorioretinal biopsies may be required 
when vitrectomy specimens are 
nondiagnostic. Because of the cytolytic 
nature of corticosteroids on lymphoma cells, 
corticosteroid treatment should be withheld 
until all diagnostic procedures are 
completed.3 
The optimal method of treatment for 
PIOL or PCNSL with ocular involvement is 
yet to be determined. Local ocular 
treatments include ocular radiotherapy6,26 
and intravitreal methotrexate.27 Due to 
radiation complications and the fact that this 
treatment cannot be repeated if the patient 
relapses, intravitreal treatment has become 
more desirable for both isolated and 
recurrent ocular disease.27,28 Extensive 
treatments include whole brain radiotherapy 
(which includes the posterior retina), high-
dose methotrexate29, cytarabine alone and in 
combination with methotrexate30-32, as well 
intrathecal chemotherapy.  
Grimm et al. retrospectively studied 83 
HIV negative, immunocompetent PIOL 
patients from 16 centers in seven 
countries.14  All had disease confined to the 
eyes at diagnosis with no evidence of brain, 
systemic, or spinal cord lymphoma.  Initial 
treatment was categorized as focal in 23 
(intra-ocular methotrexate, ocular radio-
therapy) or extensive in 53 (systemic 
chemotherapy, whole brain radiotherapy) 
patients. Six patients received no therapy 
and the details were unknown in one.  Forty-
seven patients relapsed (brain 47%, eyes 
30%, brain and eyes 15%, and systemic 
8%).  Median time to relapse was 19 
months. There was no statistically 
significant difference in progression free 
survival (PFS) or overall survival (OS) 
regardless of the treatment modality.  
Median PFS and OS were 29.6 and 58 
months, respectively, and unaffected by 
treatment type. 
Intensive chemotherapy followed by 
autologous stem-cell transplant was reported 
to rescue patients with refractory or 
recurrent PCNSL and PIOL.  A study of 22 
patients with PCNSL included 11 patients 
with PIOL (3 with isolated ocular disease 
and eight with concomitant CNS 
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involvement).33 Five of the eight patients 
with CNS disease had partial or complete 
response and had survival times of 18+ to 
70+ months. One of these patients had 
systemic progression and died in 3 months. 
Two had ocular recurrences. One had 
complete response with subsequent ocular 
radiotherapy, while the other died due to a 
second tumor.  Two of the three patients 
with isolated ocular disease had complete 
response, while the other patient with 
isolated ocular disease had intraocular 
lymphoma recurrence at three months, then 
died of a second tumor.  Only one of the 11 
patients with PIOL experienced neuro-
toxicity. Seven of the 22 patients 
experienced this side effect.  In addition, this 
treatment was not recommended for patients 
older than 60 years of age, because 5 of 7 
patients in this age group died of treatment 
complications. 
 
Conclusions 
PIOL often is misdiagnosed and patients 
should be examined for other causes of eye 
disease when considering this diagnosis.  A 
pathologic diagnosis of PIOL may not be 
found.  Cytokines help to distinguish PIOL 
from uveitis.  Neuroradiologic imaging, CSF 
examination, vitrectomy, and/or vitreous tap 
each may play a role in diagnosis.  
Depending on the patient, treatment of the 
PIOL may be focal or extensive.  Chemo-
therapy also may be necessary.  Often, 
prognosis is poor because of the disease 
progression that occurs before diagnosis. 
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